IL314055A - CRF2 router agonists and their use in therapy - Google Patents

CRF2 router agonists and their use in therapy

Info

Publication number
IL314055A
IL314055A IL314055A IL31405524A IL314055A IL 314055 A IL314055 A IL 314055A IL 314055 A IL314055 A IL 314055A IL 31405524 A IL31405524 A IL 31405524A IL 314055 A IL314055 A IL 314055A
Authority
IL
Israel
Prior art keywords
therapy
receptor agonists
crf2 receptor
crf2
agonists
Prior art date
Application number
IL314055A
Other languages
English (en)
Hebrew (he)
Inventor
Philip Janiak
Marie-Laure Ozoux
Daniela Roversi
Elisabetta Bianchi
Martina Tripepi
Alessia Santoprete
Original Assignee
Corteria Pharmaceuticals
Philip Janiak
Ozoux Marie Laure
Daniela Roversi
Elisabetta Bianchi
Martina Tripepi
Alessia Santoprete
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corteria Pharmaceuticals, Philip Janiak, Ozoux Marie Laure, Daniela Roversi, Elisabetta Bianchi, Martina Tripepi, Alessia Santoprete filed Critical Corteria Pharmaceuticals
Publication of IL314055A publication Critical patent/IL314055A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)
IL314055A 2022-02-23 2023-02-21 CRF2 router agonists and their use in therapy IL314055A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22158188.7A EP4234574A1 (en) 2022-02-23 2022-02-23 Crf2 receptor agonists and their use in therapy
PCT/EP2023/054317 WO2023161229A1 (en) 2022-02-23 2023-02-21 Crf2 receptor agonists and their use in therapy

Publications (1)

Publication Number Publication Date
IL314055A true IL314055A (en) 2024-09-01

Family

ID=80819682

Family Applications (1)

Application Number Title Priority Date Filing Date
IL314055A IL314055A (en) 2022-02-23 2023-02-21 CRF2 router agonists and their use in therapy

Country Status (15)

Country Link
US (1) US20260001928A1 (cg-RX-API-DMAC10.html)
EP (3) EP4234574A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025508820A (cg-RX-API-DMAC10.html)
KR (1) KR20240153565A (cg-RX-API-DMAC10.html)
CN (1) CN118843638A (cg-RX-API-DMAC10.html)
AU (1) AU2023224327A1 (cg-RX-API-DMAC10.html)
CA (1) CA3247142A1 (cg-RX-API-DMAC10.html)
ES (1) ES3063881T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20260115T1 (cg-RX-API-DMAC10.html)
IL (1) IL314055A (cg-RX-API-DMAC10.html)
IS (1) IS050770A (cg-RX-API-DMAC10.html)
MX (1) MX2024010296A (cg-RX-API-DMAC10.html)
PL (1) PL4482578T3 (cg-RX-API-DMAC10.html)
WO (1) WO2023161229A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202406196B (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260089954A (ko) * 2023-11-17 2026-06-16 구브라 에이/에스 hCRHR2 선택적 폴리펩타이드
WO2026064495A1 (en) * 2024-09-20 2026-03-26 Neurocrine Biosciences, Inc. Chemically modified peptides and use thereof
WO2026064486A1 (en) * 2024-09-20 2026-03-26 Neurocrine Biosciences, Inc. Chemically modified peptides and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2114437A2 (en) * 2006-10-16 2009-11-11 ConjuChem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
JOP20170153A1 (ar) 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
WO2019140030A1 (en) * 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
US12679878B2 (en) * 2020-08-19 2026-07-14 Sanofi CRF2 receptor agonists and their use in therapy

Also Published As

Publication number Publication date
EP4482578C0 (en) 2025-12-24
CA3247142A1 (en) 2023-08-31
EP4482578A1 (en) 2025-01-01
CN118843638A (zh) 2024-10-25
WO2023161229A1 (en) 2023-08-31
AU2023224327A1 (en) 2024-08-29
EP4482578B1 (en) 2025-12-24
EP4781998A2 (en) 2026-07-29
MX2024010296A (es) 2024-09-18
JP2025508820A (ja) 2025-04-10
IS050770A (is) 2024-10-15
KR20240153565A (ko) 2024-10-23
HRP20260115T1 (hr) 2026-03-13
ZA202406196B (en) 2025-03-26
ES3063881T3 (en) 2026-04-21
EP4234574A1 (en) 2023-08-30
PL4482578T3 (pl) 2026-03-16
US20260001928A1 (en) 2026-01-01

Similar Documents

Publication Publication Date Title
HRP20260115T1 (hr) Agonisti crf2 receptora i njihova primjena u terapiji
PL4199946T3 (pl) Agoniści receptora crf2 i ich zastosowanie w terapii
SI3806955T1 (sl) Agonisti receptorja glp-1 in njihova uporaba
IL310221A (en) IL12 receptor agonists and methods of using them
GB202014736D0 (en) Novel compounds and their use in therapy
IL289866A (en) Sting antibody-agonist conjugates and their use in immunotherapy
IL285715A (en) Topical rapamycin formulations and their use for the treatment of facial angiofibromas and other skin disorders
IL284053A (en) New compounds and their use in therapy
HUE067894T2 (hu) Mirdametinib és lifirafenib együttes beadása rákos megbetegedések kezelésében történõ alkalmazásra
IL316736A (en) Indazole macrocycles and their use
IL281919A (en) Combined therapy using an antibody against SSEA-4 in combination with medical oncology agents
IL304496A (en) t cells for therapeutic use
IL309249A (en) Conjugates including phosphoantigens and their use in therapy
EP4228710A4 (en) Radiolabeled therapeutic conjugates and their use in therapy
IL306148A (en) Use of ADNF peptides for treatment
IL319234A (en) Pyrazolylsulfonamide compounds and their use in therapy
IL313763A (en) Antibodies against SARS-CoV-2 SPIKE (S) and their use in the treatment of COVID-19
IL280555A (en) Converted benzamides and their use in therapy
GB202215141D0 (en) Novel cell line and its use in therapy
GB202305541D0 (en) Novel compounds and their use in therapy
GB202305546D0 (en) Novel compounds and their use in therapy
GB202001209D0 (en) Novel compounds and their use in therapy
PT4284843T (pt) Sialósidos inovadores e sua utilização em terapia
GB202110932D0 (en) Novel compounds and their use in therapy
GB202011808D0 (en) Novel compounds and their use in therapy